{"url_path":"/sec/pgny/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1551306/0001551306-26-000068-index.html","accession_number":"0001551306-26-000068","cik":"0001551306","ticker":"PGNY","issuer_name":"Progyny, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1551306/0001551306-26-000068-index.html","primary_entity_key":"0001551306","primary_entity_name":"Progyny, Inc."},"word_count":2178,"has_tables":true,"body_markdown":"pgny-20260331\n000155130612-312026Q1falseP1Yhttp://progyny.com/20260331#AccruedLiabilitiesAndOtherLiabilitiesCurrenthttp://progyny.com/20260331#AccruedLiabilitiesAndOtherLiabilitiesCurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharespgny:segmentutr:sqftxbrli:pure00015513062026-01-012026-03-3100015513062026-04-3000015513062026-03-3100015513062025-12-3100015513062025-01-012025-03-310001551306us-gaap:CommonStockMember2025-12-310001551306us-gaap:TreasuryStockCommonMember2025-12-310001551306us-gaap:AdditionalPaidInCapitalMember2025-12-310001551306us-gaap:RetainedEarningsMember2025-12-310001551306us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001551306us-gaap:CommonStockMember2026-01-012026-03-310001551306us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001551306us-gaap:TreasuryStockCommonMember2026-01-012026-03-310001551306us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001551306us-gaap:RetainedEarningsMember2026-01-012026-03-310001551306us-gaap:CommonStockMember2026-03-310001551306us-gaap:TreasuryStockCommonMember2026-03-310001551306us-gaap:AdditionalPaidInCapitalMember2026-03-310001551306us-gaap:RetainedEarningsMember2026-03-310001551306us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001551306us-gaap:CommonStockMember2024-12-310001551306us-gaap:TreasuryStockCommonMember2024-12-310001551306us-gaap:AdditionalPaidInCapitalMember2024-12-310001551306us-gaap:RetainedEarningsMember2024-12-310001551306us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-3100015513062024-12-310001551306us-gaap:CommonStockMember2025-01-012025-03-310001551306us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001551306us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001551306us-gaap:RetainedEarningsMember2025-01-012025-03-310001551306us-gaap:CommonStockMember2025-03-310001551306us-gaap:TreasuryStockCommonMember2025-03-310001551306us-gaap:AdditionalPaidInCapitalMember2025-03-310001551306us-gaap:RetainedEarningsMember2025-03-310001551306us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-3100015513062025-03-310001551306srt:MinimumMember2026-01-012026-03-310001551306srt:MaximumMember2026-01-012026-03-310001551306pgny:FertilityBenefitServicesMember2026-01-012026-03-310001551306pgny:FertilityBenefitServicesMember2025-01-012025-03-310001551306pgny:PharmacyBenefitServicesMember2026-01-012026-03-310001551306pgny:PharmacyBenefitServicesMember2025-01-012025-03-310001551306us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2026-03-310001551306us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2025-12-310001551306us-gaap:FairValueInputsLevel1Member2026-03-310001551306us-gaap:FairValueInputsLevel1Member2025-12-310001551306us-gaap:FairValueInputsLevel3Member2026-03-310001551306us-gaap:FairValueInputsLevel2Member2025-12-310001551306us-gaap:FairValueInputsLevel3Member2025-12-310001551306us-gaap:FairValueInputsLevel2Member2026-03-310001551306pgny:September2019SubleaseAgreementMember2019-09-300001551306pgny:ThroughFifthLeaseYearMemberpgny:September2019SubleaseAgreementMember2019-09-300001551306pgny:AfterFifthLeaseYearMemberpgny:September2019SubleaseAgreementMember2019-09-300001551306pgny:Februray2023LeaseAgreementMember2023-02-280001551306pgny:ThroughFifthLeaseYearMemberpgny:Februray2023LeaseAgreementMember2023-02-280001551306pgny:AfterFifthLeaseYearMemberpgny:Februray2023LeaseAgreementMember2023-02-280001551306pgny:March2025LeaseAgreementMember2025-03-310001551306pgny:ThroughFifthLeaseYearMemberpgny:March2025LeaseAgreementMember2025-03-310001551306pgny:AfterFifthLeaseYearMemberpgny:March2025LeaseAgreementMember2025-03-310001551306srt:ScenarioForecastMember2029-06-300001551306us-gaap:RevolvingCreditFacilityMemberpgny:CreditAgreementMemberus-gaap:LineOfCreditMember2025-07-0100015513062025-01-012025-12-310001551306pgny:November2025ShareRepurchaseProgramMember2025-11-300001551306pgny:November2025ShareRepurchaseProgramMember2026-03-310001551306pgny:November2025ShareRepurchaseProgramMemberus-gaap:CommonStockMember2026-01-012026-03-310001551306pgny:November2025ShareRepurchaseProgramMemberus-gaap:CommonStockMember2026-03-310001551306us-gaap:CommonStockMember2026-01-012026-03-310001551306us-gaap:CostOfSalesMember2026-01-012026-03-310001551306us-gaap:CostOfSalesMember2025-01-012025-03-310001551306us-gaap:SellingAndMarketingExpenseMember2026-01-012026-03-310001551306us-gaap:SellingAndMarketingExpenseMember2025-01-012025-03-310001551306us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001551306us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001551306us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2025-12-310001551306us-gaap:AccumulatedTranslationAdjustmentMember2025-12-310001551306us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2026-01-012026-03-310001551306us-gaap:AccumulatedTranslationAdjustmentMember2026-01-012026-03-310001551306us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2026-03-310001551306us-gaap:AccumulatedTranslationAdjustmentMember2026-03-310001551306us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-12-310001551306us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310001551306us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2025-01-012025-03-310001551306us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-03-310001551306us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2025-03-310001551306us-gaap:AccumulatedTranslationAdjustmentMember2025-03-310001551306us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2026-01-012026-03-310001551306us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2025-01-012025-03-310001551306pgny:BenefitBumpLLCMember2025-01-082025-01-080001551306us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001551306us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001551306us-gaap:EmployeeStockMember2026-01-012026-03-310001551306us-gaap:EmployeeStockMember2025-01-012025-03-310001551306us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001551306us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001551306pgny:ReportableSegmentMember2026-01-012026-03-310001551306pgny:ReportableSegmentMember2025-01-012025-03-310001551306pgny:ReportableSegmentMember2026-03-310001551306pgny:ReportableSegmentMember2025-12-310001551306pgny:PeterAnevskiMember2026-01-012026-03-310001551306pgny:PeterAnevskiMember2026-03-31\n\n[Table of](#id9afbabdceed4c78b2e77c21e334c072_7)[contents](#id9afbabdceed4c78b2e77c21e334c072_7)\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, D.C. 20549\n\n____________________________________________\n\nFORM 10-Q\n\n____________________________________________\n\n(Mark One)\n\nxQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the quarterly period ended March 31, 2026\n\nor\n\noTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from ___________________ to ___________________\n\nCommission File Number: 001-39100\n\n____________________________________________\n\nProgyny, Inc.\n\n(Exact name of registrant as specified in its charter)\n\n____________________________________________\n\nDelaware27-2220139\n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n(I.R.S. Employer\n\nIdentification No.)\n\n1359 Broadway\n\nNew York, New York\n10018\n\n(Address of principal executive offices)(Zip Code)\n\n(212) 888-3124\n\n(Registrant’s telephone number, including area code)\n\nN/A\n\n(Former name, former address and former fiscal year, if changed since last report)\n\n____________________________________________\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading Symbol(s)Name of each exchange on which registered\n\nCommon Stock,\n\n$0.0001 par value per share\nPGNYThe Nasdaq Global Select Market\n\nIndicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\nLarge accelerated filer\nx\nAccelerated filero\n\nNon-accelerated fileroSmaller reporting companyo\n\nEmerging growth companyo\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x\n\nAs of April 30, 2026, the registrant had 78,332,370 shares of common stock, $0.0001 par value per share, outstanding.\n\n[Table of](#id9afbabdceed4c78b2e77c21e334c072_7)[contents](#id9afbabdceed4c78b2e77c21e334c072_7)\n\nTable of Contents\n\nPage\n\n[PART I.](#id9afbabdceed4c78b2e77c21e334c072_16)\n\n[FINANCIAL INFORMATION](#id9afbabdceed4c78b2e77c21e334c072_16)\n\n[Item 1.](#id9afbabdceed4c78b2e77c21e334c072_19)\n\n[Financial Statements (Unaudited)](#id9afbabdceed4c78b2e77c21e334c072_19)\n\n[Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025](#id9afbabdceed4c78b2e77c21e334c072_22)\n\n[6](#id9afbabdceed4c78b2e77c21e334c072_22)\n\n[Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 2025](#id9afbabdceed4c78b2e77c21e334c072_25)\n\n[7](#id9afbabdceed4c78b2e77c21e334c072_25)\n\n[Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2026 and 2025](#id9afbabdceed4c78b2e77c21e334c072_28)\n\n[8](#id9afbabdceed4c78b2e77c21e334c072_28)\n\n[Consolidated Statements of Changes in Stockholders’ Equity for the Three Months Ended March 31, 2026 and 2025](#id9afbabdceed4c78b2e77c21e334c072_31)\n\n[9](#id9afbabdceed4c78b2e77c21e334c072_31)\n\n[Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025](#id9afbabdceed4c78b2e77c21e334c072_34)\n\n[10](#id9afbabdceed4c78b2e77c21e334c072_34)\n\n[Notes to Consolidated Financial Statements](#id9afbabdceed4c78b2e77c21e334c072_37)\n\n[11](#id9afbabdceed4c78b2e77c21e334c072_37)\n\n[Item 2.](#id9afbabdceed4c78b2e77c21e334c072_67)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#id9afbabdceed4c78b2e77c21e334c072_67)\n\n[24](#id9afbabdceed4c78b2e77c21e334c072_67)\n\n[Item 3.](#id9afbabdceed4c78b2e77c21e334c072_103)\n\n[Quantitative and Qualitative Disclosures About Market Risk](#id9afbabdceed4c78b2e77c21e334c072_103)\n\n[38](#id9afbabdceed4c78b2e77c21e334c072_103)\n\n[Item 4.](#id9afbabdceed4c78b2e77c21e334c072_106)\n\n[Controls and Procedures](#id9afbabdceed4c78b2e77c21e334c072_106)\n\n[39](#id9afbabdceed4c78b2e77c21e334c072_106)\n\n[PART II.](#id9afbabdceed4c78b2e77c21e334c072_109)\n\n[OTHER INFORMATION](#id9afbabdceed4c78b2e77c21e334c072_109)\n\n[Item 1.](#id9afbabdceed4c78b2e77c21e334c072_112)\n\n[Legal Proceedings](#id9afbabdceed4c78b2e77c21e334c072_112)\n\n[40](#id9afbabdceed4c78b2e77c21e334c072_112)\n\n[Item 1A.](#id9afbabdceed4c78b2e77c21e334c072_115)\n\n[Risk Factors](#id9afbabdceed4c78b2e77c21e334c072_115)\n\n[40](#id9afbabdceed4c78b2e77c21e334c072_115)\n\n[Item 2.](#id9afbabdceed4c78b2e77c21e334c072_118)\n\n[Unregistered Sales of Equity Securities and Use of Proceeds](#id9afbabdceed4c78b2e77c21e334c072_118)\n\n[65](#id9afbabdceed4c78b2e77c21e334c072_118)\n\n[Item 3.](#id9afbabdceed4c78b2e77c21e334c072_121)\n\n[Defaults Upon Senior Securities](#id9afbabdceed4c78b2e77c21e334c072_121)\n\n[66](#id9afbabdceed4c78b2e77c21e334c072_121)\n\n[Item 4.](#id9afbabdceed4c78b2e77c21e334c072_124)\n\n[Mine Safety Disclosures](#id9afbabdceed4c78b2e77c21e334c072_124)\n\n[66](#id9afbabdceed4c78b2e77c21e334c072_124)\n\n[Item 5.](#id9afbabdceed4c78b2e77c21e334c072_127)\n\n[Other Information](#id9afbabdceed4c78b2e77c21e334c072_127)\n\n[66](#id9afbabdceed4c78b2e77c21e334c072_127)\n\n[Item 6.](#id9afbabdceed4c78b2e77c21e334c072_130)\n\n[Exhibits](#id9afbabdceed4c78b2e77c21e334c072_130)\n\n[67](#id9afbabdceed4c78b2e77c21e334c072_130)\n\n[Signatures](#id9afbabdceed4c78b2e77c21e334c072_133)\n\n[68](#id9afbabdceed4c78b2e77c21e334c072_133)\n\n2\n\n[Table of](#id9afbabdceed4c78b2e77c21e334c072_7)[contents](#id9afbabdceed4c78b2e77c21e334c072_7)\n\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS\n\nThis Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q are forward-looking statements, including, without limitation, statements regarding our future results of operations and financial position; our ability to acquire or invest in complementary businesses, products, and technologies; our ability to achieve profitability on an annual basis and sustain such profitability; the sufficiency of our cash and cash equivalents and anticipated sources and uses of cash; our business strategies, plans, objectives and goals; our ability to acquire new clients and successfully engage new and existing clients; our ability to effectively manage our growth; our ability to compete effectively with existing competitors and new market entrants; the impact of recently adopted accounting pronouncements; our ability to attract and retain qualified employees and key personnel; the plans and objectives of management for future operations and capital expenditures; general economic and market trends; the impact of public health emergencies on our business, operations, and the markets and communities in which we and our clients, members and providers operate; and the potential impact of evolving laws and regulations, including any laws and regulations restricting reproductive rights. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.\n\nIn some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seek,” “assume,” “future,” “continue” or “aim” or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described under Part II, Item 1A. “Risk Factors” and Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Quarterly Report on Form 10-Q.\n\nIn addition, statements such as “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the filing date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.\n\nYou should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.\n\n3\n\n[Table of](#id9afbabdceed4c78b2e77c21e334c072_7)[contents](#id9afbabdceed4c78b2e77c21e334c072_7)\n\nSUMMARY OF RISKS AFFECTING OUR BUSINESS\n\nBelow is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks and uncertainties that we face, can be found under the heading “Risk Factors” in Part II, Item 1A. of this Quarterly Report on Form 10-Q and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the U.S. Securities and Exchange Commission, or the SEC, before making an investment decision regarding our common stock.\n\n•We may fail to meet our publicly announced guidance or other expectations about our business and future results of operations, which would cause our stock price to decline.\n\n•The market in which we operate is highly competitive, and, if we do not continue to compete effectively, our business, financial condition and results of operations could be harmed.\n\n•Unfavorable conditions in the global economy or our industry could limit our ability to grow our business and negatively affect our results of operations.\n\n•Our business depends on our ability to retain our existing clients and increase the adoption of our services within our client base. Any failure to do so would harm our business, financial condition and results of operations.\n\n•Our largest clients account for a significant portion of our revenue. In addition, a significant number of our clients are in the technology industry, and we generate a significant portion of our revenue from these clients. The loss of one or more of these clients, changes to pricing terms with these clients or changes within the technology industry could negatively impact our business, financial condition and results of operations.\n\n•If we are unable to attract new clients, our business, financial condition and results of operations would be adversely affected.\n\n•A significant change in the utilization of our solutions, including the consumption rate or the mix of utilization, could have an adverse effect on our business, financial condition and results of operations.\n\n•We operate in a highly regulated industry and must comply with a significant number of new and evolving legal and regulatory requirements, as well as complex judicial mandates, which could have an adverse impact on our business.\n\n•Acquisitions, strategic investments, or partnerships could be difficult to identify, pose integration challenges, divert the attention of management, disrupt our business, dilute stockholder value, and adversely affect our business, financial condition and results of operations.\n\n•We have a limited operating history with our current platform of solutions, which makes it difficult to predict our future results of operations.\n\n•The health benefits industry may be subject to negative publicity, which could adversely affect our business, financial condition and results of operations.\n\n•If our information technology systems, or those of the third parties with whom we do business, including our provider clinics, specialty pharmacies or other vendors, lag, fail or suffer cybersecurity breaches, we may experience a material disruption of our services or suffer a loss or inappropriate disclosure of confidential information, which could materially impact our business and results of operations.\n\n•Our use of artificial intelligence may subject us to new or heightened legal, regulatory, ethical, operational or other challenges.\n\n•Our business depends on our ability to maintain our Center of Excellence network of high-quality fertility specialists and other healthcare providers. If we are unable to do so, our future growth would be limited and our business, financial condition and results of operations would be harmed.\n\n•Our growth depends in part on the success of our strategic relationships with, and monitoring of, third parties, including channel partners and vendors as well as insurance carriers.\n\n4\n\n[Table of](#id9afbabdceed4c78b2e77c21e334c072_7)[contents](#id9afbabdceed4c78b2e77c21e334c072_7)\n\n•If we fail to maintain an efficient pharmacy distribution network or if there is a disruption to our network of specialty pharmacies or their supply chains or business economics, our business, financial condition and results of operations could suffer.\n\n•We are part of the broader healthcare industry and subject to increasing scrutiny, business requirements and regulation within our business, including with respect to Progyny Rx’s PBM operations, which may adversely affect our business, financial condition and results of operations.\n\nGENERAL\n\nUnless the context otherwise indicates, references in this Quarterly Report on Form 10-Q to the terms “Progyny,” “the Company,” “we,” “our” and “us” refer to Progyny, Inc. and its wholly owned subsidiaries.\n\n“Progyny®” and our other registered and common law trade names, trademarks and service marks are the property of Progyny, Inc. Other trade names, trademarks and service marks used in this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q may be referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto.\n\nWe announce material information to the public through filings with the SEC, our investor relations website at investors.progyny.com, press releases, public conference calls, and webcasts to achieve broad, non-exclusionary distribution of information. We therefore encourage investors and others interested in Progyny to review the information disclosed through such channels. Any updates to the list of disclosure channels through which we will announce information will be posted on the investor relations page on our website.\n\n5\n\n[Table of](#id9afbabdceed4c78b2e77c21e334c072_7)[contents](#id9afbabdceed4c78b2e77c21e334c072_7)\n\nPART I – FINANCIAL INFORMATION"}